Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 12:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy, Postmenopausal Women Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

NCT00620854
View directory record Official record
Conditions
Osteoporosis
Interventions
Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

NCT00532077
View directory record Official record
Conditions
Osteoporosis
Interventions
rhPTH(1-34), SB-751689 100 mg, SB-751689 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
San Diego, California • Daytona Beach, Florida • Port Orange, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT06783192
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, LNG/EE
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dried Cabernet Grapes and Cardiovascular Risk Markers

NCT03065166
View directory record Official record
Conditions
Healthy, Postmenopausal Women
Interventions
Raisin Treatment, Bagel Control
Other
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women

NCT01721993
View directory record Official record
Conditions
Healthy Postmenopausal Women
Interventions
T121, Zoledronic acid
Drug
Lead sponsor
Thar Pharmaceuticals, Inc
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems

NCT01743235
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo, Testosterone, Buspirone hydrochloride
Drug
Lead sponsor
Emotional Brain NY Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
12
States / cities
San Diego, California • Bradenton, Florida • North Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 7, 2026, 12:25 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®

NCT01096329
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

NCT01674621
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg), Abaloparatide Injection (80 mcg), Abaloparatide Placebo
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
Up to 85 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Lakewood, Colorado • Atlanta, Georgia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

NCT05438303
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density

NCT00470561
View directory record Official record
Conditions
Mammographic Breast Density
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

NCT02101203
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo, 0.5 mgTestosterone + 10 mg Buspirone
Drug
Lead sponsor
Emotional Brain NY Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 7, 2026, 12:25 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants

NCT02154984
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Obesity
Interventions
behavioral dietary intervention, telephone-based intervention, laboratory biomarker analysis
Behavioral · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women

NCT01186796
View directory record Official record
Conditions
Healthy
Interventions
Fulvestrant
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

NCT00361569
View directory record Official record
Conditions
Menopause
Interventions
DR-2041a, DR-2041b, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 1 Interventional

A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women

NCT00709540
View directory record Official record
Conditions
Osteoporosis
Interventions
ACE-011 or placebo
Biological
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 7, 2026, 12:25 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers

NCT06995482
View directory record Official record
Conditions
Healthy Postmenopausal Women
Interventions
KSHN001034, Fulvestrant
Drug
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects

NCT01487239
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C]-GDC-0980
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer

NCT00100893
View directory record Official record
Conditions
Breast Cancer
Interventions
IH636 grape seed proanthocyanidin extract
Dietary Supplement
Lead sponsor
City of Hope Medical Center
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Dexlansoprazole on Bone Homeostasis

NCT01216293
View directory record Official record
Conditions
Homeostasis, Bone and Bones
Interventions
Dexlansoprazole, Esomeprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
Up to 75 Years · Female only
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
12
States / cities
San Diego, California • Walnut Creek, California • Lakewood, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 7, 2026, 12:25 AM EDT
Recruiting Not applicable Interventional

GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women

NCT06813261
View directory record Official record
Conditions
Postmenopause, Metabolism, Geroscience
Interventions
GLYLO, Placebo
Other
Lead sponsor
Buck Institute for Research on Aging
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

NCT02364882
View directory record Official record
Conditions
Female Sexual Health
Interventions
Sildenafil
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 7, 2026, 12:25 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Effects of Aging and Estrogen on the Pituitary

NCT00386022
View directory record Official record
Conditions
Healthy
Interventions
GnRH, NAL-GLU GnRH antagonist, Estrogen patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day

NCT00649896
View directory record Official record
Conditions
Healthy
Interventions
Mylan Estradiol Transdermal System 0.025 mg/day, Climara® Transdermal System 0.025 mg/day
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years to 69 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 7, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Resveratrol in Postmenopausal Women With High Body Mass Index

NCT01370889
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
resveratrol, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 7, 2026, 12:25 AM EDT